INTRODUCTION
============

Abdominal wall--vascularized composite allotransplantation (AW-VCA) has evolved as a technically feasible option in the rare event of abdominal wall (AW) reconstruction in patients whose abdomen cannot be closed by applying conventional methods.^[@R1]--[@R3]^ As of today, all reported AW-VCAs have been performed in conjunction with either intestinal transplantation (IT) or (multi-) visceral transplantation (MVT). In such cases, factors including prior trauma, repeated laparotomies, enterocutaneous fistulae, multiple ostomy revisions, and exhaustion of local reconstructive options lead to AW loss of domain, extensive scarring, and overall poor local tissue quality.^[@R4],[@R5]^ However, successful AW revascularization in the setting of IT or MVT may pose a major challenge considering graft ischemia time, operating in a limited surgical field, and with variable recipient and donor anatomy. Several techniques have been reported to accomplish AW revascularization.^[@R6]^ None of them are considered ideal in terms of location of recipient vascular access, possible prolonged AW-VCA ischemia time, and planned reoperation. The authors conducted the first synchronous child-to-adult recipient AW-VCA using a newly described AV-loop technique in October 2018, thereby eliminating most concerns with previously described AV-VCA revascularization techniques.^[@R7]^ In the following, the patient's postoperative course, including graft monitoring, immunosuppression, and adverse events, is described in detail. Considerations for future AW-VCA are presented.

CASE REPORT
===========

The patient, a 37-year-old Army veteran with a history of perforated appendicitis during early childhood, underwent several laparotomies for lysis of adhesions and intestinal obstruction over 2 decades. In 2014, he developed a new small-bowel obstruction and presented to an outside hospital. An emergently initiated lysis of adhesions resulted in multiple inadvertent enterotomies and led to the catastrophic scenario of discontinuation of his gastrointestinal tract by proximal stapling, and an open abdomen. He was transferred to Duke University Medical Center at that time for further management. The patient became dependent on total parenteral nutrition and developed multiple high-output small-bowel enterocutaneous fistulas. In 2015--2016, he underwent several failed attempts of fistula takedown and ventral hernia repair by component separation and by the use of a biologic mesh. The patient was diagnosed with short bowel syndrome and a recurrent high-output small-bowel enterocutaneous fistula. During a prior laparotomy, 100 cm or more of native small bowel remained; however, it was considered nonfunctional, given the dense adhesions and partial high-grade obstructions observed throughout the remnant native intestine. He required recurrent hospital admissions for treatment of life-threatening bloodstream infections. In May 2018, the patient was hospitalized for dehydration due to high-output enterocutaneous fistula and was considered for a small-bowel transplantation. Because of extensive scarring and the estimation that 25%--30% of the native AW would be compromised with an additional laparotomy, there was major concern that his native AW would not be sufficient to support an anticipated small-bowel transplant (Fig. [1](#F1){ref-type="fig"}). The patient was enrolled under an Institutional Review Board (IRB)--approved protocol for abdominal wall transplantation (AWT) in conjunction with a small-bowel transplantation. The procedure was performed on October 12, 2018, after a suitable 13-year-old donor became available. The donor family agreed to donate the AW at the time of the visceral organ recovery. The patient well tolerated the 14-hour operation. The patient received Thymoglobulin (Genzyme Corp, Cambridge, Mass.) induction (1.5 mg/kg × 4 doses) and maintenance immunosuppression consisting of tacrolimus, mycophenolate mofetil (MMF), and prednisone, which is the standard immunosuppression regimen given to patients who undergo IT at Duke. The patient was extubated on postoperative day 1 and tolerated a regular diet by postoperative day 14. In the third postoperative month, the AWT developed an episode of acute cellular rejection, which responded to 5 days of steroid pulse treatment.

![Abdominal wall of the patient following multiple laparotomies, with extensive scarring and multiple recurrent enterocutaneous fistulas. It was determined that the use of conventional methods for soft-tissue closure after intestinal transplant would not be sufficient to provide adequate coverage.](gox-8-e2995-g001){#F1}

Operative Details: Creation of Arteriovenous Loop Using Saphenous Vein
----------------------------------------------------------------------

During cold ischemia time, an incision was made from the inferior aspect of the abdominal incision to the level of the mid-thigh. The saphenous vein was then transected distally and rotated proximally to allow an end-to-side anastomosis with the common femoral artery (Fig. [2](#F2){ref-type="fig"}). The arteriovenous loop was then transected and an anastomosis performed in this particular case to the donor iliac artery and vein cuff under 3.5× loupe magnification (Fig. [3](#F3){ref-type="fig"}). The procedure was performed sequentially bilaterally, and the AW-VCA was then temporarily secured to the thigh until completion of the visceral organ transplant. At that time, the in situ AW inset was performed. The bilateral inferior epigastric vasculature may be used alternatively as described by Cipriani et al,^[@R8]^ particularly in an adult AW donor where vessels' diameter is suitable.

![Creation of an arteriovenous loop using the saphenous vein with end-to-side anastomosis with common femoral artery. Figure originally published in the *American Journal of Transplantation*. Reprinted with permission.](gox-8-e2995-g002){#F2}

![Matured arteriovenous loop is transected and anastomosed end-to-end to the donor inferior epigastric vessels. Figure originally published in the *American Journal of Transplantation*. Reprinted with permission.](gox-8-e2995-g003){#F3}

The technique used has several distinct advantages, including minimizing ischemia time of the AW-VCA and decreasing total operative time as synchronous revascularization is performed in situ. In addition, this option improves the ease of anastomosis by providing additional recipient pedicle length and by elimination of further operative interventions associated with forearm banking.^[@R9]^ Limitations of this technique include additional donor-site morbidity due to bilateral thigh incisions and possible seroma formation at the level of the groin or thigh. The procedure must be modified if the saphenous vein is unavailable.

Continued Postoperative Course
------------------------------

In the immediate postoperative setting, the AW-VCA was monitored for rejection and vascular compromise using frequent clinical examination, implantable Doppler probes, and tissue oximetry. After recovery, the patient was scheduled for examinations, including skin biopsies per standard Duke Transplant Surgery protocol, and in the event that he reported any rash or other skin changes of the AW. Standard immunosuppression was continued with tacrolimus (goal trough level, 15--18 ng/ml ×3 months), MMF (1000 mg Q12 hours), and steroid taper per protocol (prednisone 20 mg daily). A standard prophylactic antibiotic and antifungal regimen given to all IT patients at Duke was initiated, which included piperacillin/tazobactam and fluconazole for 2 weeks, followed by clotrimazole for 3 months and trimethoprim/sulfamethoxazole for 1 year. At the same time, IT biopsies were performed to screen for rejection. In addition, the patient underwent scheduled skin biopsies per IRB-approved protocol for AW transplantation that led to an unnecessary amount of clinic visits and insult to the AW skin (scars). Interestingly, there was only 1 questionable episode of mild intestinal rejection (Fig. [4](#F4){ref-type="fig"}) but multiple episodes of AW-VCA rejection on biopsy (Fig. [5](#F5){ref-type="fig"}) according to the Banff Classification.^[@R10]^ The clinical and histologic appearance of an acute Banff III rejection of the AW-VCA skin are shown in Figures [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}. Despite the fact that IT rejection could not be detected in specimens, the AW-VCA rejection was treated with high doses of steroids in addition with Thymoglobulin and Clobetasol Propionate gel (1 event) (Fig. [5](#F5){ref-type="fig"}). The repeated aggressive immunosuppression treatment for AW rejection likely caused the patient to develop a fungal (Aspergillus) brain abscess in June 2019 (Fig. [8](#F8){ref-type="fig"}A), which temporarily caused headaches and right-sided weakness. The patient is currently being treated with voriconazole 400 mg twice daily. At this time, the current immunosuppression protocol includes tacrolimus (Envarsus XR), 4 mg; MMF, 500 mg twice daily; and prednisone, 12.5 mg daily. His clinical examination has returned to baseline, including a normal neurological status and no signs of weakness. After initiation of treatment with voriconazole, a follow-up brain MRI examination demonstrated a consolidated abscess formation and, subsequently, resolution of the abscess (Fig. [8](#F8){ref-type="fig"}B).

![The patient underwent intestinal biopsies bimonthly with only a single mild rejection score that resolved without additional immunotherapy treatment.](gox-8-e2995-g004){#F4}

![Schedule of skin biopsy regimen bimonthly or at any sign of clinical rejection. The patient had 4 episodes of Banff III rejection treated with Solu-Medrol (Pfizer, New York, N.Y.) and Thymoglobulin.](gox-8-e2995-g005){#F5}

![Representative findings of abdominal wall allograft during Banff III rejection episode. The abdominal wall demonstrates multiple scars from frequent skin biopsies.](gox-8-e2995-g006){#F6}

![Biopsy of abdominal wall demonstrating severe inflammation and epidermal involvement with epithelial apoptosis, dyskeratosis, and keratinolysis consistent with Banff III rejection.](gox-8-e2995-g007){#F7}

![(A) Magnetic resonance imaging of the brain demonstrates an abscess resulting in headaches and right-sided weakness. (B) The patient is currently being treated with voriconazole therapy with remarkable clinical and radiographic improvement.](gox-8-e2995-g008){#F8}

The patient is currently living with his family and pursuing a normal life. His AW transplant has continued to heal well (Fig. [9](#F9){ref-type="fig"}). He is eating a regular diet with no restrictions. Interestingly, he reports that his preoperative lactose intolerance no longer exists. Despite all setbacks, he reports that he gained a very improved quality of life and is able to pursue activities that he could not perform previously.

![Well healed allograft 10 months postoperatively from abdominal wall transplantation.](gox-8-e2995-g009){#F9}

CONSIDERATIONS FOR FUTURE ABDOMINAL WALL TRANSPLANTATION
========================================================

Surgical Technique
------------------

There have been several operative techniques described for AW transplantation involving varying vascular anastomosis and strategies to minimize cold ischemia time. Levi et al^[@R1]^ in 2003 were the first to report a procedure with end-to-side anastomosis between donor inferior epigastric artery and common iliac vessels. In 2007, Cipriani et al^[@R8]^ performed an end-to-end anastomosis between the donor and recipient inferior epigastric vessels, demonstrating that a microsurgical technique with smaller caliber vessels could be successfully used. This technique was then built upon by Giele et al^[@R9]^ in 2014, which included an additional step of banking the AW graft to the forearm vessels before a secondary anastomosis to the inferior epigastric vascular system to decrease cold ischemia time.

We suggest a variation of the technique described previously in this article, in which a donor vein graft is procured in conjunction with the AW allograft.^[@R6]^ This donor vein graft will be used to create one or bilateral arteriovenous loops of the common femoral vessels with subsequent transection and end-to-end anastomosis between each donor inferior epigastric artery bilaterally. This approach will decrease morbidity of the recipient without the need to use a saphenous vein graft. It will also decrease total operative and cold ischemia time as it allows for synchronous revascularization of AW-VCA with IT/MVT.

Biopsy Schedule
---------------

The biopsy schedule for research purposes during the postoperative period was conducted in accordance with the IRB protocol. In addition, biopsies occurred as clinically indicated for monitoring of rejection and became more necessary than initially anticipated in our patient. The AW graft was therefore subjected to many more biopsies than initially anticipated (Fig. [5](#F5){ref-type="fig"}). In retrospect, many short-interval biopsies were unnecessary and potentially caused recurrent trauma to the AW graft skin without major histopathologic changes and inferior therapeutic value. Nevertheless, studies have demonstrated that the skin has the greatest antigenicity in VCA and is an ideal diagnostic target for ease of access and early identification of graft rejection.^[@R11]^ Future combined research and clinical protocols should be "streamlined" and will have less frequent biopsies of the skin (and intestines).

Prevention of AW-VCA Chronic Rejection
--------------------------------------

The standard Duke immunosuppression protocol for IT does *not* include Alemtuzunab (Campath). The Oxford working group reported outcomes regarding immunosuppression in the largest cohort of AW-VCA. This protocol includes Alemtuzunab as induction therapy with tacrolimus as maintenance therapy. The outcome of the study demonstrated a 36% rate of rejection. Their rejection monitoring protocol included endoscopy multiple times a week for six months, followed by bimonthly monitoring. There were no scheduled skin biopsies; however, biopsies were taken if a change was noted on clinical examination. This regimen may be an alternative immunosuppression protocol that could be considered in future AW-VCA transplantation at the Duke University Medical Center.^[@R12]^

Excision of AW-VCA Skin
-----------------------

As the AW-VCA heals and IT edema resolves during the postoperative course, AW skin redundancy is noted. Therefore, excision of redundant skin along the periphery of the AW-VCA may be considered. Given that skin is the most antigenic component of VCA, excision of excess skin may theoretically decrease the antigenic load associated with AW-VCA, while improving the AW appearance. The central skin component should remain, which continues to allow for noninvasive monitoring (clinical examination).

Neurotization of AW-VCA
-----------------------

The usefulness and feasibility of neurotization in AWT have been debated. Although there have been no reported cases of neurotization in AW-VCA, Broyles et al^[@R13]^ performed a cadaveric study to determine the feasibility of neurotization in AWT. The authors were able to identify thoracolumbar nerves during their study and determined that the nerves were of adequate length and caliber to perform coaptation. However, several clinical barriers remain to neurotization in AW-VCA, including extensive scarring of the recipient AW leading to difficulty identifying nerves, as well as concerns regarding prolonging operative time. Although these obstacles exist, we may attempt neurotization at the time of future transplantations if operative factors permit.

CONCLUSIONS
===========

The field of vascularized composite allotransplantation continues to grow with improvements in immunotherapy and operative technique. We must continue to critically review surgical techniques, postoperative management, and outcomes to improve long-term patient results.
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